- Home
- OPHC vs ACRV Comparison
OPHC vs ACRV Comparison
Compare OPHC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- ACRV
- Stock Information
- Founded
- OPHC 2000
- ACRV 2018
- Country
- OPHC United States
- ACRV United States
- Employees
- OPHC N/A
- ACRV N/A
- Industry
- OPHC Major Banks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- OPHC Finance
- ACRV Health Care
- Exchange
- OPHC Nasdaq
- ACRV Nasdaq
- Market Cap
- OPHC 43.1M
- ACRV 36.1M
- IPO Year
- OPHC N/A
- ACRV 2022
- Fundamental
- Price
- OPHC $4.40
- ACRV $1.11
- Analyst Decision
- OPHC
- ACRV Buy
- Analyst Count
- OPHC 0
- ACRV 7
- Target Price
- OPHC N/A
- ACRV $17.60
- AVG Volume (30 Days)
- OPHC 14.4K
- ACRV 728.6K
- Earning Date
- OPHC 05-12-2025
- ACRV 05-14-2025
- Dividend Yield
- OPHC N/A
- ACRV N/A
- EPS Growth
- OPHC 30.24
- ACRV N/A
- EPS
- OPHC 1.33
- ACRV N/A
- Revenue
- OPHC $39,980,000.00
- ACRV N/A
- Revenue This Year
- OPHC N/A
- ACRV N/A
- Revenue Next Year
- OPHC N/A
- ACRV N/A
- P/E Ratio
- OPHC $3.30
- ACRV N/A
- Revenue Growth
- OPHC 53.28
- ACRV N/A
- 52 Week Low
- OPHC $3.53
- ACRV $1.05
- 52 Week High
- OPHC $5.90
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- OPHC 49.08
- ACRV 35.20
- Support Level
- OPHC $4.36
- ACRV $1.06
- Resistance Level
- OPHC $4.52
- ACRV $1.19
- Average True Range (ATR)
- OPHC 0.09
- ACRV 0.09
- MACD
- OPHC -0.03
- ACRV 0.05
- Stochastic Oscillator
- OPHC 11.60
- ACRV 23.53
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.